Corcept Therapeutics Says ADA And EASD Recommend Hypercortisolism Screening In Difficult-To-Control Type 2 Diabetes, Citing Its CATALYST Mifepristone Trial
Share
Why It Matters
Two big diabetes doctor groups say patients with hard to control type 2 diabetes should get screened for a hormone problem. This is good news for Corcept because their medicine treats that exact hormone problem.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.